Genedata accelerating drug development

Genedata, a Basel IT company specializing in the life sciences sector, has agreed a collaboration with Thermo Fisher. The integration of their two platforms will help accelerate the development of drugs.

Generic Image
Generic Image: Pixabay

Genedata has developed a platform for managing data from biopharmaceutical research. This platform also allows data to be brought together from different sources and then processed. The announced collaboration with international pharmaceutical and laboratory equipment supplier Thermo Fisher will now enable the direct integration of Thermo Fisher’s robotics and automation platforms with the Genedata Biopharma Platform, as was reported in a Genedata press release.

The two companies will consequently be able to offer scientists a centralized platform that delivers automation systems for sample handling, lab operations and testing and enables them to digitally trace all results for every sample of imported raw instrument data. This will accelerate the discovery and development of next-generation biotherapeutics, the Basel IT company says. Integrating the two platforms gives researchers the power to make data-based decisions and uncover insights not possible before, explained Hansjoerg Hass, Senior Director Lab Automation at Thermo Fisher.

The integration includes both laboratory instruments and software from Thermo Fisher. Both companies are implementing interfaces for the seamless integration of all areas of the two platforms. Genedata has extensive experience in projects of this kind, with the Basel company’s IT solutions having been used by other major players to automate complex laboratory workflows with lab equipment, as Othmar Pfannes, CEO of Genedata, outlines.

Handbook for Investors

Our Handbook for Investors provides valuable information about technologies and production costs, taxes and financing, as well as the legal system and infrastructure in Switzerland. Browse through the complete handbook online or download the chapters most relevant to you.

How should we contact you?

Premium Partner

Strategic partners

Institutional partner

Official program